Male subjects who are ≥ 18 years of age with histologically proven prostate cancer; and who have signed an informed consent form prior to any study related activity • Subjects who are scheduled for radical prostatectomy with ePLND.
You may not be if
Subjects who have received prior prostate cancer treatment or prior pelvic surgery;
* Subjects who have an existing medical condition that would compromise their participation in the study;
* Subjects with a history of hypersensitivity to 99mTc-nanocolloid or any excipients;
* Subjects who are unable to give voluntary, written informed consent to participate in this study;
* Subjects who are unable to understand this study and are not willing to complete all the study assessments.
Clareo Health | Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate Cancer
